Multipotent mesenchymal stromal cells and immune tolerance

References

• Friedenstein A J, Piatetzky S, II, Petrakova K V. Osteogenesis in transplants of bone marrow cells. J Embryol Exp Morphol 1966; 16: 381–390
   PubMedGoogle Scholar
• Barry F P, Murphy J M. Mesenchymal stem cells: clinical applications and biological characterization. Int J Biochem Cell Biol 2004; 36: 568–584
   PubMed Web of Science ®Google Scholar
• D'Ippolito G, Diabira S, Howard G A, Menei P, Roos B A, Schiller P C. Marrow-isolated adult multilineage inducible (MIAMI) cells, a unique population of postnatal young and old human cells with extensive expansion and differentiation potential. J Cell Sci 2004; 117: 2971–2981
   PubMed Web of Science ®Google Scholar
• Reyes M, Lund T, Lenvik T, Aguiar D, Koodie L, Verfaillie C M. Purification and ex vivo expansion of postnatal human marrow mesodermal progenitor cells. Blood 2001; 98: 2615–2625
   PubMed Web of Science ®Google Scholar
• Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006; 8: 315–317
   PubMed Web of Science ®Google Scholar
• Friedenstein A J, Chailakhjan R K, Lalykina K S. The development of fibroblast colonies in monolayer cultures of guinea-pig bone marrow and spleen cells. Cell Tissue Kinet 1970; 3: 393–403
   PubMedGoogle Scholar
• Gronthos S, Simmons P J. The biology and application of human bone marrow stromal cell precursors. J Hematother 1996; 5: 15–23
   PubMedGoogle Scholar
• Stolzing A, Scutt A. Age-related impairment of mesenchymal progenitor cell function. Aging Cell 2006; 5: 213–224
   PubMed Web of Science ®Google Scholar
• Ringden O, Le Blanc K. Allogeneic hematopoietic stem cell transplantation: state of the art and new perspectives. APMIS 2005; 113: 813–830
   PubMed Web of Science ®Google Scholar
• Kashiwakura I, Takahashi T A. Fibroblast growth factor and ex vivo expansion of hematopoietic progenitor cells. Leuk Lymphoma 2005; 46: 329–333
   PubMed Web of Science ®Google Scholar
• Pittenger M, Vanguri P, Simonetti D, Young R. Adult mesenchymal stem cells: potential for muscle and tendon regeneration and use in gene therapy. J Musculoskelet Neuronal Interact 2002; 2: 309–320
   PubMedGoogle Scholar
• Makino S, Fukuda K, Miyoshi S, Konishi F, Kodama H, Pan J, et al. Cardiomyocytes can be generated from marrow stromal cells in vitro. J Clin Invest 1999; 103: 697–705
   PubMed Web of Science ®Google Scholar
• Phinney D G, Isakova I. Plasticity and therapeutic potential of mesenchymal stem cells in the nervous system. Curr Pharm Des 2005; 11: 1255–1265
   PubMed Web of Science ®Google Scholar
• Tropel P, Platet N, Platel J C, Noel D, Albrieux M, Benabid A L, et al. Functional neuronal differentiation of bone marrow-derived mesenchymal stem cells. Stem Cells 2006; 24: 2868–2876
   PubMedGoogle Scholar
• Bhatia R, Hare J M. Mesenchymal stem cells: future source for reparative medicine. Congest Heart Fail 2005; 11: 87–91, quiz 92 – 93
   PubMedGoogle Scholar
• Muraglia A, Cancedda R, Quarto R. Clonal mesenchymal progenitors from human bone marrow differentiate in vitro according to a hierarchical model. J Cell Sci 2000; 113(Pt 7)1161–1166
   PubMed Web of Science ®Google Scholar
• Le Blanc K, Tammik C, Rosendahl K, Zetterberg E, Ringden O. HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp Hematol 2003; 31: 890–896
   PubMed Web of Science ®Google Scholar
• Tse W T, Pendleton J D, Beyer W M, Egalka M C, Guinan E C. Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation. Transplantation 2003; 75: 389–397
   PubMed Web of Science ®Google Scholar
• Djouad F, Bony C, Haupl T, Uze G, Lahlou N, Louis-Plence P, et al. Transcriptional profiles discriminate bone marrow-derived and synovium-derived mesenchymal stem cells. Arthritis Res Ther 2005; 7: R1304–R1315
   PubMed Web of Science ®Google Scholar
• Potian J A, Aviv H, Ponzio N M, Harrison J S, Rameshwar P. Veto-like activity of mesenchymal stem cells: functional discrimination between cellular responses to alloantigens and recall antigens. J Immunol 2003; 171: 3426–3434
   PubMed Web of Science ®Google Scholar
• Chan J L, Tang K C, Patel A P, Bonilla L M, Pierobon N, Ponzio N M, et al. Antigen presenting property of mesenchymal stem cells occurs during a narrow window at low levels of interferon-{gamma}. Blood 2006; 107: 4817–4824
   PubMed Web of Science ®Google Scholar
• Stagg J, Pommey S, Eliopoulos N, Galipeau J. Interferon-gamma-stimulated marrow stromal cells: a new type of nonhematopoietic antigen-presenting cell. Blood 2006; 107: 2570–2577
   PubMed Web of Science ®Google Scholar
• Krampera M, Glennie S, Dyson J, Scott D, Laylor R, Simpson E, et al. Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood 2002; 27: 27
   Google Scholar
• Bartholomew A, Sturgeon C, Siatskas M, Ferrer K, McIntosh K, Patil S, et al. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol 2002; 30: 42–48
   PubMed Web of Science ®Google Scholar
• Djouad F, Plence P, Bony C, Tropel P, Apparailly F, Sany J, et al. Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. Blood 2003; 102: 3837–3844
   PubMed Web of Science ®Google Scholar
• Glennie S, Soeiro I, Dyson P J, Lam E W, Dazzi F. Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells. Blood 2005; 105: 2821–2827
   PubMed Web of Science ®Google Scholar
• Corcione A, Benvenuto F, Ferretti E, Giunti D, Cappiello V, Cazzanti F, et al. Human mesenchymal stem cells modulate B-cell functions. Blood 2006; 107: 367–372
   PubMed Web of Science ®Google Scholar
• Angoulvant D, Clerc A, Benchalal S, Galambrun C, Farre A, Bertrand Y, et al. Human mesenchymal stem cells suppress induction of cytotoxic response to alloantigens. Biorheology 2004; 41: 469–476
   PubMed Web of Science ®Google Scholar
• Rasmusson I, Ringden O, Sundberg B, Le Blanc K. Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells. Transplantation 2003; 76: 1208–1213
   PubMed Web of Science ®Google Scholar
• Aggarwal S, Pittenger M F. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005; 105: 1815–1822
   PubMed Web of Science ®Google Scholar
• Poggi A, Prevosto C, Massaro A M, Negrini S, Urbani S, Pierri I, et al. Interaction between human NK cells and bone marrow stromal cells induces NK cell triggering: role of NKp30 and NKG2D receptors. J Immunol 2005; 175: 6352–6360
   PubMed Web of Science ®Google Scholar
• Spaggiari G M, Capobianco A, Becchetti S, Mingari M C, Moretta L. Mesenchymal stem cell-natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation. Blood 2006; 107: 1484–1490
   PubMed Web of Science ®Google Scholar
• Maitra B, Szekely E, Gjini K, Laughlin M J, Dennis J, Haynesworth S E, et al. Human mesenchymal stem cells support unrelated donor hematopoietic stem cells and suppress T-cell activation. Bone Marrow Transplant 2004; 33: 597–604
   PubMed Web of Science ®Google Scholar
• Groh M E, Maitra B, Szekely E, Koc O N. Human mesenchymal stem cells require monocyte-mediated activation to suppress alloreactive T cells. Exp Hematol 2005; 33: 928–934
   PubMed Web of Science ®Google Scholar
• Le Blanc K, Tammik L, Sundberg B, Haynesworth S E, Ringden O. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand J Immunol 2003; 57: 11–20
   PubMed Web of Science ®Google Scholar
• Rasmusson I. Immune modulation by mesenchymal stem cells. Exp Cell Res 2006; 312: 2169–2179
   PubMed Web of Science ®Google Scholar
• Jiang X X, Zhang Y, Liu B, Zhang S X, Wu Y, Yu X D, et al. Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. Blood 2005; 105: 4120–4126
   PubMed Web of Science ®Google Scholar
• Nauta A J, Kruisselbrink A B, Lurvink E, Willemze R, Fibbe W E. Mesenchymal stem cells inhibit generation and function of both CD34+-derived and monocyte-derived dendritic cells. J Immunol 2006; 177: 2080–2087
   PubMed Web of Science ®Google Scholar
• Meisel R, Zibert A, Laryea M, Gobel U, Daubener W, Dilloo D. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood 2004; 103: 4619–4621
   PubMed Web of Science ®Google Scholar
• Krampera M, Cosmi L, Angeli R, Pasini A, Liotta F, Andreini A, et al. Role for IFN-{gamma} in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells 2005; 24: 386–398
   PubMed Web of Science ®Google Scholar
• Sato K, Ozaki K, Oh I, Meguro A, Hatanaka K, Nagai T, et al. Nitric oxide plays a critical role in suppression of T cell proliferation by mesenchymal stem cells. Blood 2006; 109: 228–234
   PubMed Web of Science ®Google Scholar
• Di Nicola M, Carlo-Stella C, Magni M, Milanesi M, Longoni P D, Matteucci P, et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 2002; 99: 3838–3843
   PubMed Web of Science ®Google Scholar
• Zappia E, Casazza S, Pedemonte E, Benvenuto F, Bonanni I, Gerdoni E, et al. Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. Blood 2005; 106: 1755–1761
   PubMed Web of Science ®Google Scholar
• Plumas J, Chaperot L, Richard M J, Molens J P, Bensa J C, Favrot M C. Mesenchymal stem cells induce apoptosis of activated T cells. Leukemia 2005; 19: 1597–1604
   PubMed Web of Science ®Google Scholar
• Maccario R, Podesta M, Moretta A, Cometa A, Comoli P, Montagna D, et al. Interaction of human mesenchymal stem cells with cells involved in alloantigen-specific immune response favors the differentiation of CD4+ T-cell subsets expressing a regulatory/suppressive phenotype. Haematologica 2005; 90: 516–525
   PubMed Web of Science ®Google Scholar
• Beyth S, Borovsky Z, Mevorach D, Liebergall M, Gazit Z, Aslan H, et al. Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T-cell unresponsiveness. Blood 2005; 105: 2214–2219
   PubMed Web of Science ®Google Scholar
• Albina J E, Abate J A, Henry W L, Jr. Nitric oxide production is required for murine resident peritoneal macrophages to suppress mitogen-stimulated T cell proliferation. Role of IFN-gamma in the induction of the nitric oxide-synthesizing pathway. J Immunol 1991; 147: 144–148
   PubMed Web of Science ®Google Scholar
• Sato K, Ozaki K, Oh I, Meguro A, Hatanaka K, Nagai T, et al. Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells. Blood 2007; 109: 228–234
   PubMed Web of Science ®Google Scholar
• Devine S M, Bartholomew A M, Mahmud N, Nelson M, Patil S, Hardy W, et al. Mesenchymal stem cells are capable of homing to the bone marrow of non-human primates following systemic infusion. Exp Hematol 2001; 29: 244–255
   PubMed Web of Science ®Google Scholar
• Nauta A J, Westerhuis G, Kruisselbrink A B, Lurvink E G, Willemze R, Fibbe W E. Donor-derived mesenchymal stem cells are immunogenic in an allogeneic host and stimulate donor graft rejection in a nonmyeloablative setting. Blood 2006; 108: 2114–2120
   PubMed Web of Science ®Google Scholar
• Sudres M, Norol F, Trenado A, Gregoire S, Charlotte F, Levacher B, et al. Bone marrow mesenchymal stem cells suppress lymphocyte proliferation in vitro but fail to prevent graft-versus-host disease in mice. J Immunol 2006; 176: 7761–7767
   PubMed Web of Science ®Google Scholar
• Koc O N, Gerson S L, Cooper B W, Dyhouse S M, Haynesworth S E, Caplan A I, et al. Rapid hematopoietic recovery after coinfusion of autologous-blood stem cells and culture-expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high-dose chemotherapy. J Clin Oncol 2000; 18: 307–316
   PubMed Web of Science ®Google Scholar
• Lazarus H M, Haynesworth S E, Gerson S L, Rosenthal N S, Caplan A I. Ex vivo expansion and subsequent infusion of human bone marrow-derived stromal progenitor cells (mesenchymal progenitor cells): implications for therapeutic use. Bone Marrow Transplant 1995; 16: 557–564
   PubMed Web of Science ®Google Scholar
• Lazarus H M, Koc O N, Devine S M, Curtin P, Maziarz R T, Holland H K, et al. Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients. Biol Blood Marrow Transplant 2005; 11: 389–398
   PubMed Web of Science ®Google Scholar
• Le Blanc K, Rasmusson I, Sundberg B, Gotherstrom C, Hassan M, Uzunel M, et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 2004; 363: 1439–1441
   PubMed Web of Science ®Google Scholar
• Horwitz E M, Prockop D J, Fitzpatrick L A, Koo W W, Gordon P L, Neel M, et al. Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta. Nat Med 1999; 5: 309–313
   PubMed Web of Science ®Google Scholar